scPharmaceuticals: FUROSCIX®*(furosemide) 80mg/10mL for subcutaneous administration Commercial Day: An Investigational Treatment for Heart Failure Patients

July 5, 2022

The commercial day will feature presentations from Key Opinion Leaders Daniel Robert Bensimhon, MD (HF & Mechanical Circulatory Support Program at Cone Health) and James T. Kenney (President of JTKENNEY, LLC). Dr. Bensimhon will discuss the current treatment landscape and unmet medical need in treating adult patients with New York Heart Association (NYHA) Class II and Class III…

Read More

HTG Molecular Diagnostics: KOL Webinar on Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes

July 5, 2022

The webinar will feature a presentation from Key Opinion Leader Robert Spitale, PhD (University of California, Irvine) who will discuss the use of RNA-based platform technologies in drug discovery. The HTG Therapeutics team will introduce their proprietary transcriptome-informed drug discovery platform as the cornerstone of their differentiated approach to small molecule drug discovery. They will also discuss…

Read More

KOL Webinar on a Novel Approach to Cardiovascular Treatment: CorMatrix’s ECM Technology

July 5, 2022

The KOL Webinar will feature presentations from Key Opinion Leaders (KOL), including Dr. Marc Gerdisch (Franciscan St. Francis Health). We will discuss the current treatment landscape and unmet clinical challenges of valvular heart disease and repairing and regenerating the heart wall after myocardial infarction. The CorMatrix’s extracellular matrix (ECM) technology, and its products, Cor®Tricuspid ECM® Valve and…

Read More

A Novel Approach in Solid Tumors: Updates on Alpha Tau’s Recent and Upcoming Alpha DaRT Trials

June 27, 2022

Join us for the Hybrid Alpha Tau KOL Breakfast Event, which will feature presentations from Key Opinion Leaders (KOLs) Michael J. Zelefsky, MD (Memorial Sloan Kettering Cancer Center), Mark D’Andrea, MD (University Cancer Centers) and Robert Den, MD (Alpha Tau’s Chief Medical Officer) who will discuss the science behind Alpha Tau’s therapy (the Alpha DaRT radiation technology) and its clinical…

Read More

ChromDex: The Transforming Benefits of Nicotinamide Riboside, Featuring Dr. Charles Brenner

June 27, 2022

The webinar will feature a presentation from Key Opinion Leader (KOL) Charles Brenner, PhD (City of Hope National Medical Center) who will discuss the latest research on Nicotinamide Riboside (NR) and its many benefits as a precursor to Nicotinamide Adenine Dinucleotide (NAD). NAD is the central catalyst to multiple metabolic processes and a critical ally to resilience and…

Read More

MediWound EscharEx Investor Breakfast

June 23, 2022

Join us for the MediWound EscharEx Investor Day, featuring presentations by Key Opinion Leaders (KOLs) John C. Lantis, M.D. (Mount Sinai West Hospital and Icahn School of Medicine), Cyaandi R. Dove, D.P.M. (Advanced Wound & Ankle Center, Las Vegas), Robert J. Snyder, D.P.M., M.Sc. (Barry University) and Kevin Feng (Oliver Wyman). These external experts will discuss the current wound…

Read More

LifeSci Partners Genetic Medicines Symposium

June 22, 2022

LifeSci Partners is hosting our 2nd Annual virtual Genetic Medicines Symposium on June 28th and 29th and will consist of virtual discussions with key opinion leaders (KOLs), as well as presentations/fireside chats with 30+ public and private companies focused on the development of genetic medicines. The potential of genetic medicines has never been greater, spanning…

Read More

Science37: The Operating System that enables Hybrid/Agile Clinical Trials: Accelerating Timelines & Optimizing Cost Savings

June 21, 2022

The traditional clinical trial model has not changed significantly in > 60 years. This event will feature how Science37’s decentralized clinical trials model is disrupting the traditional model by enabling Sponsors to achieve a shorter trial start-up, accelerated patient enrollment, better retention, and more diverse participants resulting in maximized time and cost savings to accelerate breakthrough clinical research.…

Read More

Cidara Therapeutics: Research & Development Day

June 17, 2022

The virtual R&D day will feature a panel discussion with Key Opinion Leaders (KOLs) in oncology Ezra Cohen, MD, FRCPSC, FASCO (San Diego Center for Precision Immunotherapy), Perry Nisen, MD, PhD (CEO and Executive Chairman of Quanta), and with Les Tari, PhD (Cidara’s Chief Scientific Officer). The discussion will be focused on Cidara’s Cloudbreak® platform which couples potent inhibitors to…

Read More

Oncocyte: Expert Webinar on the role of DetermaIO and the Tumor Microenvironment in Clinical Practice

June 15, 2022

The webinar will feature presentations from Key Opinion Leaders (KOLs) Chiara Cremolini, MD, PhD (Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy) and Adam Brufsky, MD, PhD (University of Pittsburgh School of Medicine). Dr. Cremolini will provide an expert data overview on the ASCO 2022 poster session: An immune-related gene expression profile to…

Read More